<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394093</url>
  </required_header>
  <id_info>
    <org_study_id>17494</org_study_id>
    <nct_id>NCT02394093</nct_id>
  </id_info>
  <brief_title>To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.</brief_title>
  <acronym>Icicle</acronym>
  <official_title>An Open Label Crossover Pharmacokinetic Trial of Aspirin Dry Powder Versus Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the bioavailability of a single oral dose of the Acetylsalicylic Acid containing
      dry powder 500 mg in comparison to the bioavailability of a single oral dose of aspirin
      tablets and aspirin effervescent tablets in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by AUC0-t</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by AUC0-∞</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>AUC0-∞ : AUC from zero to infinity after single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by Cmax</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by tmax</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>tmax: time to reach maximum drug concentration in plasma after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by λz (Kel)</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose</time_frame>
    <description>λz (Kel) : Apparent terminal rate constant, calculated from the slope of a log-linear regression of the unweighted data considering the last concentration-time points &gt; LLOQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by t1/2</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by t lag</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>t lag : Lag-time (time delay between drug administration and first observed concentration above LLOQ (Lower limit of quantification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by Cmax/AUC0-∞</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetyl salicylic Acid (ASA) characterized by MRT</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>MRT :Mean residence time (for extravascular and iv bolus administration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by AUC0-t</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by AUC0-∞</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>AUC0-∞ : AUC from zero to infinity after single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by Cmax</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by tmax</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>tmax: time to reach maximum drug concentration in plasma after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by λz (Kel)</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>λz (Kel) : Apparent terminal rate constant, calculated from the slope of a log-linear regression of the unweighted data considering the last concentration-time points &gt; LLOQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by t1/2</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by t lag</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>t lag : Lag-time (time delay between drug administration and first observed concentration above LLOQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by Cmax/AUC0-∞</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by MRT</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>MRT :Mean residence time (for extravascular and iv bolus administration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Acetylsalicylic Acid (ASA) characterized by AUC0-t /AUC0-∞</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Salicylic Acid (SA) characterized by AUC0-t /AUC0-∞</measure>
    <time_frame>baseline (pre-dose), 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 50, 55 minutes and 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as measure of safety and tolerability</measure>
    <time_frame>Up to 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <arm_group>
    <arm_group_label>Aspirin dry powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Acetylsalicylic Acid (ASA) dry powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin coated tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg ASA coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin effervescent tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg ASA effervescent tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin (Acetylsalicylic acid, BAYe4465)</intervention_name>
    <description>One stick pack containing 500 mg acetylsalicylic acid dry powder</description>
    <arm_group_label>Aspirin dry powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin (Acetylsalicylic acid, BAYe4465)</intervention_name>
    <description>One tablet containing 500 mg acetylsalicylic acid</description>
    <arm_group_label>Aspirin coated tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin (Acetylsalicylic acid, BAYe4465)</intervention_name>
    <description>One effervescent tablet containing 500 mg acetylsalicylic acid</description>
    <arm_group_label>Aspirin effervescent tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy ,male and female subjects 18 to 55 years of age, inclusive

          -  Body Mass Index (BMI) of approximately 18 to 30 kg/m2, and a total body weight &gt;50 kg
             (110 lbs)

          -  Results of screening and clinical laboratory tests are within normal limits or
             considered not clinically significant by the Principal Investigator or Sponsor

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control for at least 1 month prior to screening (3 months on oral
             contraceptives), e.g., oral or patch contraceptives, intrauterine device,
             intramuscular injection or double-barrier and have a negative pregnancy test at
             Screening and on Day 0 of each treatment period. Female subjects of nonchildbearing
             potential must be amenorrheic for at least 2 years or had a hysterectomy and/or
             bilateral oophorectomy.

        Exclusion Criteria:

          -  History of hypersensitivity to acetylsalicylic acid (ASA), naproxen sodium,
             acetaminophen, other non-steroidal anti-inflammatory drugs (NSAIDs), and similar
             pharmacological agents or components of the products

          -  History of gastrointestinal bleeding or perforation, including bleeding related to
             previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two
             or more distinct episodes of proven ulceration or bleeding).

          -  Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (OTC or
             prescription) seven days prior to dosing or during the Treatment Periods, other than
             study product

          -  Loss of blood in excess of 500 mL within 56 days of the first dose of trial treatment
             (e.g., donation, plasmapheresis, or injury)

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic disease,
             or malignancies

          -  Positive alcohol or drug screen at Screening or on Day 0 of Treatment Periods 1,2 and
             3

          -  Females who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2015</study_first_submitted>
  <study_first_submitted_qc>March 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

